AngioDynamics/$ANGO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About AngioDynamics
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
Ticker
$ANGO
Sector
Primary listing
Employees
675
Headquarters
Website
AngioDynamics Metrics
BasicAdvanced
$433M
-
-$0.83
0.60
-
Price and volume
Market cap
$433M
Beta
0.6
52-week high
$13.50
52-week low
$5.83
Average daily volume
382K
Financial strength
Current ratio
2.209
Quick ratio
1.296
Long term debt to equity
4.321
Total debt to equity
5.545
Profitability
EBITDA (TTM)
-1.662
Gross margin (TTM)
53.92%
Net profit margin (TTM)
-11.62%
Operating margin (TTM)
-8.23%
Effective tax rate (TTM)
0.11%
Revenue per employee (TTM)
$430,000
Management effectiveness
Return on assets (TTM)
-5.03%
Return on equity (TTM)
-17.50%
Valuation
Price to revenue (TTM)
1.487
Price to book
2.39
Price to tangible book (TTM)
3.83
Price to free cash flow (TTM)
-29.817
Free cash flow yield (TTM)
-3.35%
Free cash flow per share (TTM)
-0.357
Growth
Revenue change (TTM)
-3.76%
Earnings per share change (TTM)
-81.87%
3-year revenue growth (CAGR)
-2.57%
10-year revenue growth (CAGR)
-1.85%
3-year earnings per share growth (CAGR)
6.93%
10-year earnings per share growth (CAGR)
24.24%
What the Analysts think about AngioDynamics
Analyst ratings (Buy, Hold, Sell) for AngioDynamics stock.
Bulls say / Bears say
Med Tech net sales rose 22.0% year-over-year to $35.8 million in Q4 FY25, marking the third consecutive quarter of >20% Med Tech segment growth (Nasdaq)
H.C. Wainwright raised its buy rating on ANGO to ‘Buy’ and boosted its price target to $16, citing the company’s strong financial performance and strategic transformation in its Med Tech business (Ainvest)
The FDA’s 510(k) clearance of the AlphaVac System for pulmonary embolism treatment enhances AngioDynamics’ regulatory standing and opens a new high-growth market, supporting future Med Tech revenue expansion (Markets Insider)
Despite accelerating revenue, AngioDynamics remains unprofitable with a GAAP net loss of $6.1 million (EPS $0.15) in Q4 FY25 and a full-year loss of $34.0 million (EPS $0.83), limiting near-term earnings momentum (Nasdaq)
Tariff-related headwinds trimmed gross margin by approximately 204 basis points in Q4 FY25 and are expected to cost $4–6 million in FY26, posing an ongoing margin pressure risk (Nasdaq)
Fiscal 2026 guidance forecasts an adjusted loss per share of $0.25–$0.35, wider than Wall Street’s $0.23 projection, highlighting continued near-term profitability challenges (Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.
AngioDynamics Financial Performance
Revenues and expenses
AngioDynamics Earnings Performance
Company profitability
AngioDynamics News
AllArticlesVideos
AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb Ischemia
Business Wire2 months ago
AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology
Business Wire2 months ago
AngioDynamics 'Exceptionally Well-Positioned' For 2026, CEO Says: But Tariffs Still Sting
Benzinga2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for AngioDynamics stock?
AngioDynamics (ANGO) has a market cap of $433M as of September 16, 2025.
What is the P/E ratio for AngioDynamics stock?
The price to earnings (P/E) ratio for AngioDynamics (ANGO) stock is 0 as of September 16, 2025.
Does AngioDynamics stock pay dividends?
No, AngioDynamics (ANGO) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next AngioDynamics dividend payment date?
AngioDynamics (ANGO) stock does not pay dividends to its shareholders.
What is the beta indicator for AngioDynamics?
AngioDynamics (ANGO) has a beta rating of 0.6. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.